secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091319
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech Q2 net revenue $17.4M (+40% QoQ); DFD-29 Phase 3 positive, cosibelimab PDUFA Jan 2024
--------------------------------------------------------------------------------

- Total net revenue $17.4M in Q2 2023, a 40% increase from $12.4M in Q1 2023; dermatology products contributed $17.0M.
- DFD-29 Phase 3 trials for rosacea met co-primary and all secondary endpoints vs placebo and Oracea; NDA submission expected H2 2023.
- Cosibelimab BLA accepted with PDUFA date Jan 3, 2024; new longer-term data showed 55% ORR and 23% CR in locally advanced cSCC.
- Cash, equivalents and restricted cash $89.2M at June 30, 2023, down from $181.0M at Dec 31, 2022.
- Bylaws amended to clarify stockholder voting majority requirement; effective August 10, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465923091319/0001104659-23-091319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465923091319/tm2323520d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer